Eczema, Atopic

15 registered clinical trials studyying Eczema, Atopic — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD NCT07441395	Corvus Pharmaceuticals, Inc.	Phase 2
Active Not Recruiting	A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema NCT07216027	Pfizer	Phase 2
Recruiting	Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. NCT06855745	Alphyn Biologics	Phase 2
Active Not Recruiting	Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic De NCT06554847	Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.	Phase 3
Completed	A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis NCT06436183	Apollo Therapeutics Ltd	Phase 2
Active Not Recruiting	Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis NCT05642208	Nantes University Hospital	Phase 4
Unknown	Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema NCT05913791	National University of Singapore	N/A
Terminated	A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) W NCT05732454	Pfizer	Phase 2 / Phase 3
Recruiting	Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive NCT05575882	NAOS Argentina S.A.	N/A
Completed	The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Ecz NCT05003453	RDC Clinical Pty Ltd	Phase 2 / Phase 3
Completed	Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis NCT03568136	GWT-TUD GmbH	Phase 2
Completed	A Study in Subjects With Moderate Atopic Dermatitis NCT03175354	Ralexar Therapeutics, Inc.	Phase 2
Completed	Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis NCT03050151	Regeneron Pharmaceuticals	Phase 1
Terminated	Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4) NCT00671528	Organon and Co	Phase 4
Completed	Long-term Safety of Protopic in Atopic Eczema NCT00560378	Astellas Pharma Inc	Phase 3